TY - JOUR
T1 - Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
AU - Villemagne, Victor L.
AU - Okamura, Nobuyuki
N1 - Funding Information:
We thank Professors Christopher Rowe, Yukitsuda Kudo, Colin Masters, Kazuhiko Yanai, Shozo Furumoto, Drs Ryuichi Harada and Michelle Fodero-Tavoletti, and Louis F Destouches, Mrs Svetlana Pejoska-Bozinovski, Ms Fiona Lamb, and the Brain Research Institute for their assistance with this study. This review was supported in part by NHMRC Project Grant 1044361 . VLV is supported by NHMRC Research Fellowship 1046471 . The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis and treatment of primary and secondary tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The cross-sectional and longitudinal assessment of the temporal and spatial patterns of tau deposition in the brain will allow a better understanding of the role tau plays in ageing as well as its relationship with cognition, genotype, and neurodegeneration. It is likely that selective tau imaging could be used as a diagnostic and prognostic biomarker of disease progression, as well as a surrogate marker for monitoring of efficacy and patient recruitment for disease-specific therapeutic trials.
AB - In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis and treatment of primary and secondary tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The cross-sectional and longitudinal assessment of the temporal and spatial patterns of tau deposition in the brain will allow a better understanding of the role tau plays in ageing as well as its relationship with cognition, genotype, and neurodegeneration. It is likely that selective tau imaging could be used as a diagnostic and prognostic biomarker of disease progression, as well as a surrogate marker for monitoring of efficacy and patient recruitment for disease-specific therapeutic trials.
UR - http://www.scopus.com/inward/record.url?scp=84941985175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941985175&partnerID=8YFLogxK
U2 - 10.1016/j.conb.2015.09.002
DO - 10.1016/j.conb.2015.09.002
M3 - Review article
AN - SCOPUS:84941985175
VL - 36
SP - 43
EP - 51
JO - Current Opinion in Neurobiology
JF - Current Opinion in Neurobiology
SN - 0959-4388
ER -